<body><a name="drugname"></a><table class="topbox" width="100%">
<tr>
<td><span class="topboxgenname">TELMISARTAN</span><br/>(tel-mi-sar'tan)<br/><span class="topboxtradename">Micardis<br/></span><b>Classifications:</b> <span class="classification">cardiovascular agent</span>; <span class="classification">antihypertensive</span>; <span class="classification">angiotensin ii receptor antagonist</span><br/><b>Prototype: </b>Losartan potassium<br/><b>Pregnancy Category: </b> C  (D in second and third trimester)<br/></td>
</tr>
</table>
<h1><a name="avail">Availability</a></h1>
<p>40 mg, 80 mg tablets</p>
<h1><a name="action">Actions</a></h1>
<p>Angiotensin II receptor (type AT<sub>1</sub>) antagonist. Selectively blocks the binding of angiotensin II to the AT<sub>1</sub> receptors in many tissues (e.g., vascular smooth muscles, adrenal glands).
      </p>
<h1><a name="therapef">Therapeutic Effects</a></h1>
<p>Blocks the vasoconstricting and aldosterone-secreting effects of angiotensin II, thus resulting in an antihypertensive effect.
         Indicated by a reduction in BP.
      </p>
<h1><a name="uses">Uses</a></h1>
<p>Treatment of hypertension.</p>
<h1><a name="contrain">Contraindications</a></h1>
<p>Hypersensitivity to telmisartan or other angiotensin receptor antagonists (e.g., losartan, eprosartan, etc.); pregnancy [(category
         C) first trimester, (category D) second and third trimester], lactation.
      </p>
<h1><a name="precaution">Cautious Use</a></h1>
<p>Coronary artery disease (CAD); hypertropic cardiomyopathy; CHF; oliguria; hypotension; renal artery stenosis; older adult
         patients; biliary obstruction; liver dysfunction; renal impairment. Safety and efficacy in children 
      </p><h1><a name="rtedsg">Route &amp; Dosage</a></h1>
<table cellpadding="4" cellspacing="0" class="rdbox" width="100%">
<tr>
<td><span class="indicationtitle">Hypertension</span><br/><span class="rdage">Adult:</span> <span class="rdroute">PO</span> 40 mg q.d., may increase to 80 mg/d<br/></td>
</tr>
</table>
<h1><a name="admintn">Administration</a></h1><span class="adminroutetype">Oral</span><br/><ul>
<li>Do not remove tablets from blister pack until immediately before administration.</li>
<li>Correct volume depletion prior to initial dose.</li>
<li>Store at 15°30° C (59°86° F).</li>
</ul>
<h1><a name="adverse">Adverse Effects (<img src="../images/special/greaterorequal.gif"/>1%)</a></h1><span class="typehead">Body as a Whole:</span> Back pain, flu-like syndrome, myalgia, headache, fatigue. <span class="typehead">CNS:</span> Dizziness. <span class="typehead">CV:</span> Hypotension, hypertension, chest pain, peripheral edema. <span class="typehead">GI:</span> Diarrhea, dyspepsia, abdominal pain, nausea. <span class="typehead">Respiratory:</span> Sinusitis, pharyngitis. 
      <h1><a name="interactions">Interactions</a></h1><span class="typehead">Drug:</span> <b>Telmisartan</b> may increase <b>digoxin</b> levels. 
      <h1><a name="pharmaks">Pharmacokinetics</a></h1><span class="typehead">Absorption:</span> Absorption is dose dependent, 42% of 40 mg dose is absorbed. <span class="typehead">Peak:</span> 0.51 h. <span class="typehead">Distribution:</span> &gt;99% protein bound. <span class="typehead">Metabolism:</span> Minimally metabolized. <span class="typehead">Elimination:</span> Primarily excreted in feces as unchanged drug. <span class="typehead">Half-Life:</span> 24 h. 
      <h1><a name="nursing"><span class="implictitle">Nursing Implications</span></a></h1>
<p><span class="adeffecttitle">Assessment &amp; Drug Effects</span></p>
<ul>
<li>Monitor BP carefully after initial dose; and periodically thereafter. Monitor more frequently with preexisting biliary obstructive
            disorders or hepatic insufficiency.
         </li>
<li>Monitor dialysis patients closely for orthostatic hypotension.</li>
<li>Lab tests: Periodic Hgb, creatinine clearance, liver enzymes.</li>
<li>Monitor concomitant digoxin levels throughout therapy.</li>
</ul>
<p><span class="eductitle">Patient &amp; Family Education</span></p>
<ul>
<li>Report pregnancy to physician immediately.</li>
<li>Allow between 24 wk for maximum therapeutic response.</li>
<li>Do not breast feed while taking this drug.</li>
</ul>
<hr/>
<p><span class="footer">Common adverse effects in <i>italic</i>, life-threatening effects <u>underlined</u>; generic names in <b>bold</b>; classifications in <small>SMALL CAPS</small>; <img border="0" src="../images/maple.gif"/> Canadian drug name; <img border="0" src="../images/pr.gif"/> Prototype drug</span></p>
</body>